Pioglitazone could induce remission in major depression: a meta-analysis

Romain Colle,1,* Delphine de Larminat,1,* Samuel Rotenberg,1 Franz Hozer,1 Patrick Hardy,1 Céline Verstuyft,2 Bruno Fève,3,* Emmanuelle Corruble1,* 1Psychiatry Department, Hôpital Bicêtre, INSERM, UMR S1178, University Paris-Sud, Assistance Publique-H&o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Pioglitazone Major Depressive Episode Major Depressive Disorder Bipolar Disorder Remission Meta-analysis. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/27f9bb453900437199bbf7f35fcfce02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:27f9bb453900437199bbf7f35fcfce02
record_format	dspace
spelling	oai:doaj.org-article:27f9bb453900437199bbf7f35fcfce022021-12-02T02:31:29ZPioglitazone could induce remission in major depression: a meta-analysis1178-2021https://doaj.org/article/27f9bb453900437199bbf7f35fcfce022016-12-01T00:00:00Zhttps://www.dovepress.com/pioglitazone-could-induce-remission-in-major-depression-a-meta-analysi-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Romain Colle,1,* Delphine de Larminat,1,* Samuel Rotenberg,1 Franz Hozer,1 Patrick Hardy,1 Céline Verstuyft,2 Bruno Fève,3,* Emmanuelle Corruble1,* 1Psychiatry Department, Hôpital Bicêtre, INSERM, UMR S1178, University Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; 2Molecular Genetic, Pharmacogenetics and Hormonology Department, Hôpital Bicêtre, INSERM UMR_S1184, Centre IMVA, University Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; 3Endocrinology Department, INSERM UMR_S938, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Sorbonne Universités, Université Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, Paris, France *These authors contributed equally to this work Background: Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes, the optimal clinical target for an antidepressant drug, is a matter of concern. Indeed, only one out of four double-blind randomized controlled trials show higher remission rates with pioglitazone than with control treatments. Hence, the main aim of this study was to perform a meta-analysis of the efficacy of pioglitazone for the treatment of MDE, focusing on remission rates.Methods: Four double-blind randomized controlled trials, comprising 161 patients with an MDE, were included in this meta-analysis. Pioglitazone was studied either alone (one study) or as add-on therapy to conventional treatments (antidepressant drugs or lithium salts). It was compared either to placebo (three studies) or to metformin (one study). Remission was defined by a Hamilton Depression Rating Scale score <8 after treatment.Results: Pioglitazone could induce higher remission rates than control treatments (27% versus 10%, I2=17.3%, fixed-effect model: odds ratio [OR] =3.3, 95% confidence interval [95% CI; 1.4; 7.8], P=0.008). The OR was even higher in the subgroup of patients with major depressive disorder (n=80; 23% versus 8%, I2=0.0%; fixed-effect model: OR =5.9, 95% CI [1.6; 22.4], P=0.009) and in the subgroup of patients without metabolic comorbidities (n=84; 33% versus 10%, I2=0.0%; fixed-effect model: OR =5.1, 95% CI [1.5; 17.9], P=0.01). As compared to control treatments, results suggest six patients would need to be treated with pioglitazone in order to achieve the possibility of one more remission.Conclusion: Pioglitazone, either alone or as add-on therapy to conventional treatments, could induce remission of MDE, suggesting that drugs with PPAR-γ agonist properties may be true and clinically relevant antidepressants, even in patients without metabolic comorbidities. Keywords: pioglitazone, major depressive episode, major depressive disorder, bipolar disorder, remission, meta-analysisColle Rde Larminat DRotenberg SHozer FHardy PVerstuyft CFève BCorruble EDove Medical PressarticlePioglitazoneMajor Depressive EpisodeMajor Depressive DisorderBipolar DisorderRemissionMeta-analysis.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 9-16 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pioglitazone Major Depressive Episode Major Depressive Disorder Bipolar Disorder Remission Meta-analysis. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Pioglitazone Major Depressive Episode Major Depressive Disorder Bipolar Disorder Remission Meta-analysis. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Colle R de Larminat D Rotenberg S Hozer F Hardy P Verstuyft C Fève B Corruble E Pioglitazone could induce remission in major depression: a meta-analysis
description	Romain Colle,1,* Delphine de Larminat,1,* Samuel Rotenberg,1 Franz Hozer,1 Patrick Hardy,1 Céline Verstuyft,2 Bruno Fève,3,* Emmanuelle Corruble1,* 1Psychiatry Department, Hôpital Bicêtre, INSERM, UMR S1178, University Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; 2Molecular Genetic, Pharmacogenetics and Hormonology Department, Hôpital Bicêtre, INSERM UMR_S1184, Centre IMVA, University Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; 3Endocrinology Department, INSERM UMR_S938, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Sorbonne Universités, Université Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, Paris, France *These authors contributed equally to this work Background: Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes, the optimal clinical target for an antidepressant drug, is a matter of concern. Indeed, only one out of four double-blind randomized controlled trials show higher remission rates with pioglitazone than with control treatments. Hence, the main aim of this study was to perform a meta-analysis of the efficacy of pioglitazone for the treatment of MDE, focusing on remission rates.Methods: Four double-blind randomized controlled trials, comprising 161 patients with an MDE, were included in this meta-analysis. Pioglitazone was studied either alone (one study) or as add-on therapy to conventional treatments (antidepressant drugs or lithium salts). It was compared either to placebo (three studies) or to metformin (one study). Remission was defined by a Hamilton Depression Rating Scale score <8 after treatment.Results: Pioglitazone could induce higher remission rates than control treatments (27% versus 10%, I2=17.3%, fixed-effect model: odds ratio [OR] =3.3, 95% confidence interval [95% CI; 1.4; 7.8], P=0.008). The OR was even higher in the subgroup of patients with major depressive disorder (n=80; 23% versus 8%, I2=0.0%; fixed-effect model: OR =5.9, 95% CI [1.6; 22.4], P=0.009) and in the subgroup of patients without metabolic comorbidities (n=84; 33% versus 10%, I2=0.0%; fixed-effect model: OR =5.1, 95% CI [1.5; 17.9], P=0.01). As compared to control treatments, results suggest six patients would need to be treated with pioglitazone in order to achieve the possibility of one more remission.Conclusion: Pioglitazone, either alone or as add-on therapy to conventional treatments, could induce remission of MDE, suggesting that drugs with PPAR-γ agonist properties may be true and clinically relevant antidepressants, even in patients without metabolic comorbidities. Keywords: pioglitazone, major depressive episode, major depressive disorder, bipolar disorder, remission, meta-analysis
format	article
author	Colle R de Larminat D Rotenberg S Hozer F Hardy P Verstuyft C Fève B Corruble E
author_facet	Colle R de Larminat D Rotenberg S Hozer F Hardy P Verstuyft C Fève B Corruble E
author_sort	Colle R
title	Pioglitazone could induce remission in major depression: a meta-analysis
title_short	Pioglitazone could induce remission in major depression: a meta-analysis
title_full	Pioglitazone could induce remission in major depression: a meta-analysis
title_fullStr	Pioglitazone could induce remission in major depression: a meta-analysis
title_full_unstemmed	Pioglitazone could induce remission in major depression: a meta-analysis
title_sort	pioglitazone could induce remission in major depression: a meta-analysis
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/27f9bb453900437199bbf7f35fcfce02
work_keys_str_mv	AT coller pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT delarminatd pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT rotenbergs pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT hozerf pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT hardyp pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT verstuyftc pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT feveb pioglitazonecouldinduceremissioninmajordepressionametaanalysis AT corrublee pioglitazonecouldinduceremissioninmajordepressionametaanalysis
_version_	1718402398020435968

Pioglitazone could induce remission in major depression: a meta-analysis

Ejemplares similares